; (II) during 2021, of at least 100 percent in the preceding 12 months or of at least 150 percent in the preceding 24 months; (III) during 2022, of at least 100 percent in the preceding 12 months or of at least 200 percent in the preceding 36 months; (IV) during 2023, of at least 100 percent in the preceding 12 months or of at least 250 percent in the preceding 48 months; or (V) on or after January 1, 2024, of at least 100 percent in the preceding 12 months or of at least 300 percent in the preceding 60 months. (B) High spending with increase The drug— (i) was in the top 50th percentile of net spending under title XVIII or XIX (to the extent data is available) during any 12-month period in the preceding 60 months; and (ii) per dose, had an increase in the wholesale acquisition cost, with respect to determinations made— (I) during 2020, of at least 15 percent since the date of the enactment of this section; (II) during 2021, of at least 15 percent in the preceding 12 months or of at least 20 percent in the preceding 24 months; (III) during 2022, of at least 15 percent in the preceding 12 months or of at least 30 percent in the preceding 36 months; (IV) during 2023, of at least 15 percent in the preceding 12 months or of at least 40 percent in the preceding 48 months